Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 11:44 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 889–912 of 5,058 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Capsule 2 Clear all

Conditions: Healthy
Interventions: Amlodipine and Benazepril HCl Capsules 10 mg/20 mg, Lotrel® Capsules 10 mg/20 mg; Drug
Lead sponsor: Mylan Pharmaceuticals Inc; Industry
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Healthy Volunteers
Interventions: Olomorasib test, Olomorasib reference; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Daytona Beach, Florida

Conditions: Irritable Bowel Syndrome
Interventions: Citalopram, Placebo; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2009
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Endometrial Cancer, ARID1A Gene Mutation, Recurrent Endometrial Carcinoma
Interventions: Avelumab, M1774; Drug
Lead sponsor: Panagiotis Konstantinopoulos, MD, PhD; Other
Eligibility: 18 Years and older · Female only
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Hepatitis C Virus Infection
Interventions: Simeprevir, Sofosbuvir; Drug
Lead sponsor: Janssen Infectious Diseases BVBA; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 310 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 38
States / cities: Dothan, Alabama • Bakersfield, California • Chula Vista, California + 35 more

Conditions: Cocaine Dependence, Cocaine Addiction, Cocaine Abuse, Substance Abuse
Interventions: Placebo, Rivastigmine 3 mg, Huperzine A 0.4 mg, Rivastigmine 6 mg, Huperzine A 0.8 mg; Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years to 55 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Hypertension (HTN), Hypertension
Interventions: Arugula Extract, Psyllium Husk; Dietary Supplement
Lead sponsor: Baylor University; Other
Eligibility: 18 Years to 50 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Waco, Texas

Conditions: Healthy
Interventions: Topiramate Sprinkle Capsules 25 mg, Topamax® Sprinkle Capsules 25 mg; Drug
Lead sponsor: Mylan Pharmaceuticals Inc; Industry
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Uterine Fibroids
Interventions: Epigallocatechin gallate (EGCG), Clomiphene Citrate, Letrozole; Dietary Supplement · Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Healthy Volunteers
Interventions: Treprostinil Palmitil Inhalation Powder, Placebo; Drug
Lead sponsor: Insmed Incorporated; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Autosomal Dominant Polycystic Kidney Disease
Interventions: Tolvaptan MR, Tolvaptan IR; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 6
States / cities: Boston, Massachusetts • Minneapolis, Minnesota • Rochester, Minnesota + 3 more

Conditions: Sleep Disturbance, Opioid-use Disorder
Interventions: Suvorexant, Placebos; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 21 Years to 65 Years
Enrollment: 249 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 5
States / cities: Baltimore, Maryland • Bel Air, Maryland • Elkton, Maryland

Conditions: CNS Lymphoma
Interventions: Zanubrutinib, Methotrexate, Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin, Prednisone; Drug
Lead sponsor: Juan P. Alderuccio, MD; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Diabetes Mellitus, Diabetes Mellitus, Type 2, Glucose Metabolism Disorders
Interventions: PF-04991532, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: PT001 MDI, Tiotropium Bromide, PT001 Placebo MDI; Drug
Lead sponsor: Pearl Therapeutics, Inc.; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 10
States / cities: Fullerton, California • Clearwater, Florida • Panama City, Florida + 7 more

Conditions: Polycystic Ovarian Syndrome
Interventions: Flax Seed Oil, Fish Oil, Soybean Oil; Dietary Supplement
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Hyperoxaluria, Nonalcoholic Fatty Liver Disease, Kidney Stone
Interventions: BMN 255, Placebo; Drug
Lead sponsor: BioMarin Pharmaceutical; Industry
Eligibility: 18 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 7
States / cities: Birmingham, Alabama • Chula Vista, California • Chula Vista Isles, Florida + 4 more

Conditions: Dyslipidemias, High Cholesterol, Hypercholesterolemia
Interventions: Obicetrapib, Ezetimibe 10mg, Obicetrapib placebo, Ezetimibe placebo; Drug · Other
Lead sponsor: NewAmsterdam Pharma; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 16
States / cities: Los Angeles, California • Northridge, California • Ocala, Florida + 13 more

Conditions: Diabetic Neuropathic Pain
Interventions: ABT-652 6 mg, ABT-652 12 mg, ABT-652 12 mg - 18 mg, Placebo, Duloxetine; Drug
Lead sponsor: AbbVie (prior sponsor, Abbott); Industry
Eligibility: 18 Years to 75 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 8
States / cities: Anaheim, California • Walnut Creek, California • Milford, Connecticut + 5 more

Conditions: Cushing Syndrome, Neoplasms
Interventions: Dabigatran Etexilate, Relacorilant; Drug
Lead sponsor: Corcept Therapeutics; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Relapsed/Refractory Follicular Lymphoma, Marginal Zone Lymphoma
Interventions: Zanubrutinib, Rituximab, Lenalidomide, Obinutuzumab; Drug
Lead sponsor: BeOne Medicines; Industry
Eligibility: 18 Years and older
Enrollment: 799 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2030
U.S. locations: 50
States / cities: Fresno, California • Irvine, California • Los Alamitos, California + 43 more

Conditions: SARS-CoV-2, COVID-19
Interventions: Hydroxychloroquine, Azithromycin, Placebo oral tablet; Drug
Lead sponsor: Salomeh Keyhani MD; Federal
Eligibility: 216 Months and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Pain, Neuropathic, Pain, Inflammatory
Interventions: AFA-281; Drug
Lead sponsor: Afasci Inc; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Los Alamitos, California

Conditions: Alzheimer s Disease
Interventions: Terazosin (Hytrin), Placebo; Drug · Other
Lead sponsor: Qiang Zhang; Other
Eligibility: 50 Years to 80 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2032
U.S. locations: 1
States / cities: Iowa City, Iowa

Search by objective public record fields.

Fasting Study of Amlodipine and Benazepril HCl Capsules 10 mg/20 mg to Lotrel® Capsules 10 mg/20 mg

A Study Comparing Two Ways of Taking Olomorasib (LY3537982) in Healthy Participants

Citalopram in Irritable Bowel Syndrome

Avelumab and M1774 in ARID1A-mutated Endometrial Cancer

Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Chronic Hepatitis C Virus Infection Without Cirrhosis

Rivastigmine and Huperzine A as Treatments for Cocaine Dependence

Under Pressure: Arugula Extract's Effect on Blood Pressure in Hypertensive Individuals

Fed Study of Topiramate Sprinkle Capsules 25 mg and Topamax® Sprinkle Capsules 25 mg

Pharmacokinetics and Hepatic Safety of EGCG

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder (TPIP) in Healthy Participants

Dose-finding Study of New Tolvaptan Formulation in Subjects With ADPKD

Examining the Role of the Orexin System in Sleep and Stress in Persons With Opioid Use Disorder

Zanubrutinib in Combination With Pola-R-CHP and High-dose Methotrexate in Patients With Secondary CNS Lymphoma

Single Dose Study of PF-04991532 in Healthy Subjects

PT001 MDI Versus Spiriva® in Patients With Moderate to Severe COPD

Compare Effects of Flax Seed Oil, and Fish Oil on Blood Sugar Levels

A Study of BMN 255 in Participants With Non-Alcoholic Fatty Liver Disease And Hyperoxaluria

Study to Evaluate the Effect of Obicetrapib in Combination With Ezetimibe as an Adjunct to HIS Therapy

A Study Comparing the Efficacy and Safety of ABT-652 to Placebo in Subjects With Diabetic Neuropathic Pain

Effect of Relacorilant on the Pharmacokinetics of the Sensitive P-glycoprotein Substrate Dabigatran Etexilate in Healthy Participants

A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma

VA Remote and Equitable Access to COVID-19 Healthcare Delivery (VA-REACH TRIAL)

Phase I Single Ascending Dose and Multiple Ascending Doses of Oral AFA-281 in Healthy Volunteers

Terazosin And Metabolic Engagement in Alzheimer's Disease